Abbott Laboratories (ABT)
NYSE · Abbott Park, Illinois, USA · Founded 1888 · CEO Robert Ford
Valuation summary
$126.93 fair value versus $103.87 in the market, a difference of +22.2%. Rated Buy.
| Fair value per share | $126.93 |
| Current share price | $103.87 |
| Upside / downside | +22.2% |
| Bear case | $82.50 |
| Bull case | $191.70 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.60% |
| Market capitalisation | $180B |
| EV / Sales | 3.9x |
About Abbott Laboratories
Founded in 1888 by physician Wallace Abbott. Robert Ford has been CEO since 2020. Abbott spans four quite different businesses: medical devices, diagnostics, established pharmaceuticals sold mainly in emerging markets, and nutrition products including Similac and Ensure. The acquisition of Exact Sciences added Cologuard and a cancer screening franchise to diagnostics. Its most important growth asset is FreeStyle Libre, a continuous glucose monitor that has become the standard of care for diabetes management and is expanding into non-insulin-dependent users.
Investment case
- FreeStyle Libre is a category leader in a large and still-underpenetrated diabetes market.
- Genuine diversification across four businesses smooths the earnings profile.
- Structural heart and electrophysiology device franchises are growing well above company average.
Key risks
- COVID testing revenue has fully normalised, creating a multi-year comparison drag.
- Ongoing litigation relating to preterm infant formula creates a tail risk that is hard to size.
- Dexcom competes directly and aggressively in continuous glucose monitoring.
Recent developments
- 2026-10-21 · Q3 sales up 14.5% to $13.0bn with Exact Sciences added, 7% comparable; 2026 adjusted EPS narrowed to $5.50-$5.55 source
- 2026-10-02 · Rothschild & Co Redburn upgraded Abbott to Buy with a $127 target, saying Exact Sciences strengthens diagnostics growth and margins. source
- 2026-09-30 · Abbott launched SimpleScreen CRC, a Freenome-developed blood test for colorectal cancer screening, alongside its stool-based Cologuard Plus. source
- 2026-09-14 · Abbott agreed to pay $385m to resolve DOJ, whistleblower and state claims over the 2022 Sturgis infant formula recall; criminal investigation closed. source
Revenue by segment
| Medical Devices | 45% |
| Diagnostics | 22% |
| Nutrition | 18% |
| Established Pharmaceuticals | 15% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $52.8B | $9.1B |
| Year 2 | $58.0B | $10.0B |
| Year 3 | $63.6B | $10.9B |
| Year 4 | $69.7B | $11.9B |
| Year 5 | $76.2B | $13.0B |
What the street says
Viewed as a steady, defensive compounder. Rothschild & Co Redburn upgraded the shares to Buy in October 2026, arguing Exact Sciences strengthens diagnostics growth and margins; the $385m settlement in September 2026 closed the government's 2022 formula recall case, leaving preterm formula litigation and Libre growth as the main swing factors.
Comparable companies: MDT · AZN · TMO · SNY · IDXX · SYK · ISRG · A
Open the interactive model, price chart and sensitivity grid →